AVIR
HOLD / NEUTRALNeutralComposite
61.70
Technical
73.20
Fundamental
54.00
Rank
—
Price
5.07
Hurst
0.45
As of
Aug 14, 2026
Daily
Atea Pharmaceuticals, Inc.
HealthcareBiotechnologyAtea Pharmaceuticals is a biopharmaceutical company developing oral medications to treat viral infections. The company's primary program combines two drug candidates—bemnifosbuvir and ruzasvir—currently in Phase 3 testing for hepatitis C, while also pursuing AT-587 in earlier-stage trials for chronic hepatitis E infection. Atea operates a proprietary technology platform for creating antiviral compounds and maintains a partnership with MSD International for ruzasvir development.
Market cap
$329.6M
P/E (trailing)
—
P/E (forward)
-2.78
PEG ratio
—
Dividend yield
0.00%
Beta
0.39
52w range
2.87 – 6.45
Return on equity
-58.14%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 4.11 (+26.5%) · range 2.96–6.15
Cycle position
15/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 95 · STRONG SETUP · exit proximity 0
Conviction
55/ 100 · maturity 0%
Buildup.335
EMA entry setup.4295
Fundamentals.2554
Volume profile
POC
4.42
Price vs POC
-7.1%
Overhead supply
96%
Runway
+5.6%
Value area 4.15–5.15 · 96% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +3.91% | +13.87% | mature |
| 40d | -1.76% | +13.87% | mature |